Finally, repeated measures analysis of variance showed the mBI outcome to be influenced by the MS clinical phenotype (PP-MS/SP-MS vs. RR-MS) (p = 0.018) but not by any of the AQP4 gene SNPs. This evidence concerns the gene AQP4 and myeloid sarcoma.